Company profile

Brett P. Monia
Incorporated in
Fiscal year end
Former names
Isis Pharmaceuticals Inc
IRS number

IONS stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


6 May 20
11 Jul 20
31 Dec 20


Company financial data Financial data

Quarter (USD) Mar 20 Dec 19 Sep 19 Jun 19
Revenue 133.37M 493.68M 167.89M 163.81M
Net income -58.48M 203.96M 18.43M -10.01M
Diluted EPS -0.35 1.28 0.18 -0.01
Net profit margin -43.85% 41.31% 10.98% -6.11%
Operating income -61.13M 260.65M 2.52M -18.83M
Net change in cash -197.09M 435.35M -24.58M -103.29M
Cash on hand 486.2M 683.29M 247.94M 272.52M
Cost of revenue 2.55M 1.01M 967K 1.36M
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue 1.12B 599.67M 507.67M 346.62M
Net income 303.26M 214.99M -10.78M -60.4M
Diluted EPS 2.08 2.07 0.15 -0.5
Net profit margin 27.01% 35.85% -2.12% -17.43%
Operating income 365.88M -61.37M 31.05M -20.16M
Net change in cash 404.47M 149.19M 44.95M -44.11M
Cash on hand 683.29M 278.82M 129.63M 84.69M
Cost of revenue 4.38M 1.82M NaN 0

Financial data from company earnings reports

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
6 Jul 20 Muto Frederick T Common Stock Option exercise Aquire M No 0 667 0 31,683
6 Jul 20 Berthelsen Spencer R Common Stock Option exercise Aquire M No 0 667 0 100,983
6 Jul 20 Berthelsen Spencer R RSU Common Stock Option exercise Dispose M No 0 667 0 666
6 Jul 20 Wender Joseph H Common Stock Option exercise Aquire M No 0 667 0 65,805
6 Jul 20 Muto Frederick T RSU Common Stock Option exercise Dispose M No 0 667 0 666
6 Jul 20 Wender Joseph H RSU Common Stock Option exercise Dispose M No 0 667 0 666
6 Jul 20 Castleman Breaux Common Stock Option exercise Aquire M No 0 667 0 19,183
6 Jul 20 Castleman Breaux RSU Common Stock Option exercise Dispose M No 0 667 0 666
2 Jul 20 Berthelsen Spencer R Common Stock Option exercise Aquire M No 0 889 0 100,316
2 Jul 20 Muto Frederick T Common Stock Option exercise Aquire M No 0 889 0 31,016
13F holders
Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Largest transactions
Shares Bought/sold Change

Financial report summary

  • If the market does not accept our medicines, including SPINRAZA, TEGSEDI and WAYLIVRA, and our medicines in development, we are not likely to generate substantial revenues or become consistently profitable.
  • If we or our partners fail to compete effectively, our medicines, including SPINRAZA, TEGSEDI and WAYLIVRA, and our medicines in development, will not contribute significant revenues.
  • Certain of our medicines may compete with our other medicines, which could reduce our expected revenues.
  • Our medicines could be subject to regulatory limitations following approval.
  • We depend on our collaboration with Biogen for the development and commercialization of SPINRAZA.
  • If Akcea cannot optimize and maintain effective marketing and sales capabilities or enter into agreements with third parties to market and sell TEGSEDI and WAYLIVRA, we may not generate significant product revenue from TEGSEDI or WAYLIVRA.
  • If government or other third-party payors fail to provide adequate coverage and payment rates for our medicines, including SPINRAZA, TEGSEDI and WAYLIVRA, and our medicines in development, our revenue will be limited.
  • If Biogen cannot manufacture finished drug product for SPINRAZA or the post-launch supply of the active drug substance for SPINRAZA, SPINRAZA may not maintain commercial success.
  • If we or our partners fail to obtain regulatory approval for our medicines and additional approvals for SPINRAZA, TEGSEDI and WAYLIVRA, and our medicines in development, we or our partners cannot sell them in the applicable markets.
  • If the results of clinical testing indicate that any of our medicines are not suitable for commercial use, we may need to abandon one or more of our drug development programs.
  • Even if our medicines are successful in preclinical and human clinical studies, the medicines may not be successful in late-stage clinical studies.
  • If we cannot manufacture our medicines or contract with a third party to manufacture our medicines at costs that allow us to charge competitive prices to buyers, we cannot market our products profitably.
  • We depend on third parties to conduct our clinical studies for our medicines and any failure of those parties to fulfill their obligations could adversely affect our development and commercialization plans.
  • We have incurred losses, and our business will suffer if we fail to consistently achieve profitability in the future.
  • Our ability to use our net operating loss carryovers and certain other tax attributes may be limited.
  • Since corporate partnering is a significant part of our strategy to fund the development and commercialization of our development programs, if any of our collaborative partners fail to fund our collaborative programs, or if we cannot obtain additional partners, we may have to delay or stop progress on our drug development programs.
  • Even with funding from corporate partners, if our partners do not effectively perform their obligations under our agreements with them, it would delay or stop the progress of our drug development and commercial programs.
  • If we do not progress in our programs as anticipated, the price of our securities could decrease.
  • If we cannot protect our patent rights or our other proprietary rights, others may compete more effectively against us.
  • Intellectual property litigation could be expensive and prevent us from pursuing our programs.
  • If we fail to obtain timely funding, we may need to curtail or abandon some of our programs.
  • If our planned management transition is not successful our business could suffer.
  • The loss of key personnel, or the inability to attract and retain highly skilled personnel, could make it more difficult to run our business and reduce our likelihood of success.
  • If the price of our securities continues to be highly volatile, this could make it harder for you to liquidate your investment and could increase your risk of suffering a loss.
  • We are exposed to potential product liability claims, and insurance against these claims may not be available to us at a reasonable rate in the future or at all.
  • We are dependent on information technology systems, infrastructure and data, which exposes us to data security risks.
  • Because we use biological materials, hazardous materials, chemicals and radioactive compounds, if we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.
  • If a natural or man-made disaster strikes our research, development or manufacturing facilities or otherwise affects our business, it could delay our progress developing and commercializing our medicines.
  • Provisions in our certificate of incorporation, convertible notes documents, call spread hedge transaction documents and Delaware law may prevent stockholders from receiving a premium for their shares.
  • Future sales of our common stock in the public market could adversely affect the trading price of our securities.
  • Our business is subject to changing regulations for corporate governance and public disclosure that has increased both our costs and the risk of noncompliance.
  • Changes in tax laws, regulations and treaties could affect our future taxable income.
  • We could be subject to additional tax liabilities.
  • Negative conditions in the global credit markets and financial services and other industries may adversely affect our business.
Management Discussion
  • In this Report on Form 10-Q, unless the context requires otherwise, “Ionis,” “Company,” “we,” “our,” and “us,” means Ionis Pharmaceuticals, Inc. and its majority owned affiliate, Akcea Therapeutics, Inc.
  • In addition to historical information contained in this Report on Form 10-Q, the Report includes forward-looking statements regarding our business and the therapeutic and commercial potential of SPINRAZA (nusinersen), TEGSEDI (inotersen), WAYLIVRA (volanesorsen) and our technologies and products in development, including the business of Akcea Therapeutics, Inc., our majority-owned affiliate. Any statement describing our goals, expectations, financial or other projections, intentions or beliefs, is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including those related to the impact COVID-19 could have on our business, and including but not limited to those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Our forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in this report and described in additional detail in our annual report on Form 10-K for the year ended December 31, 2019, which is on file with the U.S. Securities and Exchange Commission and is available from us, and those identified within Part II Item 1A. Risk Factors of this Report. Although our forward-looking statements reflect the good faith judgment of our management, these statements are based only on facts and factors currently known by us. As a result, you are cautioned not to rely on these forward-looking statements.
  • We are a leader in discovering and developing RNA-targeted therapeutics. We have created an efficient and broadly applicable drug discovery platform leveraging our expertise in antisense oligonucleotide therapeutics that we believe has fundamentally changed medicine and transformed the lives of people with devastating diseases. Our large, diverse and advancing pipeline has over 40 potential first-in-class and/or best-in-class medicines designed to address a broad range of diseases, including neurological, cardiovascular, infectious and pulmonary diseases. The medicines in our pipeline address patients with diseases ranging from rare to common. We have three commercial medicines approved in major markets around the world, SPINRAZA, TEGSEDI and WAYLIVRA. We have four medicines in pivotal studies, tominersen for Huntington’s disease, tofersen for SOD1-ALS, AKCEA-APO(a)-LRx for cardiovascular disease, or CVD, and AKCEA-TTR-LRx for TTR amyloidosis.
Content analysis ?
H.S. freshman V good
New words: Accredo, accrual, acquisition, advisory, aggregate, American, Amsterdam, amyloid, antidilutive, Blueprint, Brexit, brought, budget, bulk, calendar, Cambridge, captioned, Caribbean, carryback, centralized, centronuclear, chain, Chancery, chemistry, Circuit, Commonwealth, competitor, complaint, complementary, contractor, Counsel, Court, CVD, deficient, deny, Department, deviate, disagree, discrete, dismissal, dismissed, disproportionate, distract, District, doubled, EAP, eased, Education, elevated, EMA, emergency, Empirico, enrichment, epidemic, essentially, evolve, expiry, Fast, feedback, fiduciary, field, fill, firmly, fluctuate, fluid, formal, formally, foundation, franchise, frequent, furlough, goal, Governor, hedge, hedging, heightened, highlighting, home, HORIZON, impede, improperly, incentivize, inhibit, intertwined, irrespective, issuable, judicial, kidney, Lancet, length, licensor, magnitude, mandate, millionif, mind, movement, Myalept, NASH, nonalcoholic, occupy, OLE, oncology, oral, outbreak, outweigh, outweighed, pandemic, passed, phishing, physician, plaintiff, pocket, power, PPACA, PPD, prejudice, proceeding, prohibiting, PTO, pulmonary, purported, pursuant, rapidly, reach, rebate, recession, Reconciliation, referendum, regular, reinstated, released, relocated, relocation, remanded, remote, removed, reorganization, reorganize, repeal, resignation, resolved, rest, resumed, Retirement, ruling, site, situated, situation, solicited, spread, statute, stay, strain, strength, strike, subscription, suspension, tailoring, teleconferencing, tominersen, travel, Trump, UK, unchanged, unclear, unconstitutional, Union, unjust, unmet, unrelated, unviable, unwinding, upheld, videoconferencing, vision, volume, voluntarily, vupanorsen, warrant, withdrew, workforce
Removed: abnormal, acquired, adipose, adjacent, adjusted, afflicting, aim, alongside, AMD, anniversary, apply, ASC, augment, Boston, cadre, classification, clinic, closing, Codification, commenced, commencement, commonly, comparison, compromising, continuously, controlled, correlation, coupled, deadly, degeneration, deletion, demonstrating, discontinued, diversification, dosed, dry, ending, enrolled, entity, expectation, fat, firdapse, flexibility, FPL, free, GA, GAAP, Galien, Germany, GILTI, growing, HD, incidence, insulin, intangible, integrate, judgmental, laquinimod, leading, leased, leasing, lessor, letter, lipodystrophy, liver, macular, manageable, maximum, measuring, medium, metreleptin, mid, Morgan, National, necessarily, newly, NICE, notice, observed, occupancy, October, opening, orphan, partially, payor, penetrate, planned, positioned, practical, preclude, precluded, preliminary, preparing, prevail, Prix, region, reldesemtiv, representing, requirement, resistance, revolving, risdiplam, secondarily, selected, serve, space, spectrum, Stanley, step, sublease, submit, sustained, tenant, tissue, today, Toronto, transform, transformative, unaffordable, unidentified